Patients taking a daily weight-loss pill lost up to 12% of their body weight in a global trial, according to the Cornell Chronicle.
The study tested orforglipron, an oral GLP-1 drug, in over 3,100 adults with obesity or related conditions. Weight loss increased with higher doses, and heart and metabolic health also improved. Results were published Sept. 17 in the New England Journal of Medicine.
Unlike popular GLP-1 injections, this pill form doesn’t need cold storage — a potential game-changer for global access. The trial was sponsored by Eli Lilly, which makes the drug.
FingerLakes1.com is the region’s leading all-digital news publication. The company was founded in 1998 and has been keeping residents informed for more than two decades. Have a lead? Send it to [email protected].